WASHINGTON, Dec. 8 (UPI) -- White House Office of Health Reform chief Nancy-Ann DeParle earned more than $6.6 million as a paid director for U.S. healthcare firms, records indicate.
A study by the Investigative Reporting Workshop at American University and a review by The Washington Times of U.S. Securities and Exchange Commission records revealed that some of the firms DeParle was associated with were targeted by government investigations or whistle-blower lawsuits on suspicions of billing fraud and other legal problems, the newspaper reported Tuesday.
The Times said most of the companies -- such as DaVita Inc., Boston Scientific Corp., Guidant Corp. and Specialty Laboratories Inc. -- have a vested interest in outcome of the healthcare
industry reform measures now being considered by the Congress.
Steve Ellis of Taxpayers for Common Sense told the newspaper: "We want to look at it to be sure there was no conflict. We need to look at the end to see who wins and who loses."
DeParle has resigned from her corporate directorships, promising to remove herself from any matters directly involving the companies. Her spokeswoman, Linda Douglass, told the Times there was no conflict between her healthcare reform work and corporate board posts. UPI Article